Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Responses to BCG Vaccination in Malawi and the UK
NCT00241657Phase 2Completed
- Sponsor
- London School of Hygiene & Tropical Medicine
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of bcg vaccine in Tuberculosis (TB) (2 cohorts), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoints: Delayed-type hypersensitivity and Cytokine responses to mycobacterial antigens. Status: completed.
02
Drugs
bcg vaccine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT00241657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00241657.